Does Urolithin A Cross the Blood-Brain Barrier? What the Research Shows
Key takeaways
- The blood-brain barrier is a tightly controlled filter; most large or water-loving molecules are kept out, so "does it get in?" is a real and important question.
- In silico (computer-model) work predicts urolithin A is small and lipophilic enough to cross — a prediction, not a measurement.
- ANIMAL studies have reported urolithin A in brain tissue and shown it switching on mitophagy genes and reducing neuroinflammation in the brain. All of this is PRECLINICAL.
- No HUMAN trial has measured urolithin A in brain tissue or tested it for cognition; the only human brain data is indirect and observational.
- Direct supplementation produces far higher blood levels than diet alone, which is the peripheral exposure any brain effect would have to build on.
It's one of the most sensible questions you can ask about any compound marketed for "brain" or "cellular" benefits: can it even get into the brain? The brain is guarded by the blood-brain barrier, a specialized lining of blood-vessel cells that lets oxygen, glucose, and a short list of approved molecules through while blocking the vast majority of circulating substances. A compound that can't cross it can still act on the body, but it can't act directly on neurons.
For urolithin A — a metabolite your gut bacteria make from the ellagitannins in pomegranates, walnuts, and berries — the honest answer is a qualified "the early evidence points to yes, but it's almost entirely preclinical." Here's what the research actually shows, and where it stops.
What is the blood-brain barrier, and why is crossing it hard?
The blood-brain barrier isn't a wall so much as a highly selective gate. The cells lining the brain's blood vessels are stitched together by tight junctions and backed by pumps that actively eject foreign molecules. In general, a compound has a better chance of passing if it is small, fat-soluble (lipophilic), and not a target of those efflux pumps. Many promising compounds fail this test, which is why "crosses the BBB" is a meaningful credential and not a given.
Urolithin A is a small phenolic molecule, which is a promising starting point. But in the body it is rapidly converted into phase II conjugates (glucuronide and sulfate forms), and those bulkier, more water-loving metabolites face a harder path across the barrier — a wrinkle that makes the question more interesting than a simple yes/no.
What does the computer modeling predict?
Early in silico (computer-prediction) analyses modeled the physical and chemical properties of urolithins and concluded that urolithin A and B were likely to penetrate the blood-brain barrier, whereas the larger pomegranate precursors were not. This is useful as a hypothesis generator, but it is a prediction based on a molecule's structure — not a measurement of the compound actually appearing in brain tissue. It tells you crossing is plausible, nothing more. This work is summarized in independent scientific reviews of urolithin A's aging research (scoping review, 2023).
What have animal studies found in brain tissue?
This is where the evidence gets more concrete — and where the PRECLINICAL label must stay firmly attached. Several rodent studies report both the presence of urolithin A in the brain and biological activity there:
| Study (model) | What was observed | Evidence level |
|---|---|---|
| APP/PS1 mice (Gong et al., 2019) | Reduced amyloid-beta deposition and neuroinflammation; improved memory performance | PRECLINICAL (mouse) |
| Alzheimer's-model mice (Kshirsagar et al., 2022) | Upregulation of mitophagy genes PINK1 (~2.6-fold) and Parkin (~2.3-fold) in brain | PRECLINICAL (mouse) |
| 3xTg & APP/PS1 mice (Hou et al., 2024) | Restored mitophagy and lysosomal function; mitigated cognitive decline and tau pathology | PRECLINICAL (mouse + cells) |
| Rodent brain-detection work | Urolithin A measurable in brain tissue after dosing | PRECLINICAL (animal) |
The Gong study reported that urolithin A attenuated memory impairment and neuroinflammation in a widely used Alzheimer's mouse model (Gong et al., 2019). Work in other Alzheimer's-model mice found that urolithin A upregulated the mitophagy-associated genes PINK1 and Parkin in the brain (Kshirsagar et al., 2022), and a 2024 study reported that it restored mitophagy and lysosomal function and improved cognition in mouse models (Hou et al., 2024). In vitro work using an engineered barrier model has also reported that urolithins and their conjugates can cross a blood-brain-barrier layer and dampen inflammatory signaling in microglia (Food & Function, 2025).
Taken together, these findings are genuinely encouraging for the hypothesis that urolithin A reaches the brain and does something there. What they are not is proof that it does so in people, at supplement doses, with any clinical benefit.
What about human evidence?
Here the record is thin, and honesty requires saying so plainly. No human trial has directly measured urolithin A concentrations in living brain tissue, and none has tested it as a cognition or dementia intervention. The human data that exists is peripheral or observational:
First, exposure. A randomized trial showed that direct supplementation produced blood levels of urolithin A roughly six-fold higher than drinking pomegranate juice (Singh et al., 2022; HUMAN). That establishes the peripheral exposure any brain effect would have to build from — but blood is not brain. Second, an observational signal: in a dietary trial, higher urinary urolithin A levels were associated with less age-related hippocampal volume loss on MRI. Because the diet was rich in many polyphenols, that association cannot be pinned on urolithin A specifically. It's a hypothesis, not a result.
So what's the bottom line for someone taking it?
If your interest in urolithin A is specifically about the brain, the current evidence supports cautious curiosity, not confident expectation. The mechanism is plausible and the animal data is consistent, but the human brain evidence hasn't been generated yet. The better-established human findings for urolithin A are in muscle and mitochondrial function, not cognition.
That framing is worth keeping in mind whichever way you take it — whether through diet or a standardized form such as SOMA Urolithin A gummies. Supporting general cellular and mitochondrial health is a reasonable, evidence-informed goal; expecting a specific cognitive outcome is getting ahead of the science.
Frequently asked questions
Does urolithin A definitely cross the blood-brain barrier in humans?
Not definitely. Computer models predict it can, and animal studies have detected it in brain tissue, but no human study has directly measured urolithin A in the living human brain. The human-specific answer is still unknown.
Is the brain research on urolithin A from human studies?
Almost entirely no. The brain findings come from cell and rodent models, which is why they're labeled PRECLINICAL. The only human brain-related data is observational and can't isolate urolithin A from other dietary factors.
Do the gut-produced conjugates of urolithin A reach the brain too?
This is an active research question. The phase II conjugates (glucuronide and sulfate forms) are more water-loving and harder to transport across the barrier, though some barrier-model work suggests they can cross. The in-brain picture in humans is not yet established.
Would a higher dose get more into the brain?
Higher doses raise blood levels, and direct supplementation produces much higher blood levels than diet. But more in the blood does not automatically mean more in the brain, and no human dosing study has mapped brain uptake. This isn't a reason to exceed labeled amounts.
Should I take urolithin A for memory or cognition?
There's no human clinical evidence supporting urolithin A as a memory or cognition treatment, and it isn't intended to diagnose, treat, cure, or prevent any condition. If cognitive health is a concern, that's a conversation to have with a qualified healthcare professional.
Support your cellular health, every day
SOMA delivers a high-potency 1,000 mg dose of Urolithin A in one simple daily gummy — no guesswork, no converter-status lottery.
Shop SOMA Urolithin A Gummies →These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.